
    
      This study will assess the safety and tolerability of AMG 330 in combination with
      pembrolizumab and whether pembrolizumab will enhance the anti-AML activity of AMG 330. Both
      cohort 1 and 2 will include AMG 330 and pembrolizumab with the difference being the
      initiation date for pembrolizumab treatment.
    
  